Literature DB >> 15149318

Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.

Chrishan S Samuel1, Chongxin Zhao, Courtney P Bond, Tim D Hewitson, Edward P Amento, Roger J Summers.   

Abstract

BACKGROUND: Relaxin (RLX) is a peptide hormone that stimulates the breakdown of collagen in preparation for parturition and when administered to various models of induced fibrosis. However, its significance in the aging kidney is yet to be established. In this study, we compared structural and functional changes in the kidney of aging relaxin-1 (RLX-/-) deficient mice and normal (RLX+/+) mice.
METHODS: The kidney cortex and medulla of male and female RLX+/+ and RLX-/- mice at various ages were analyzed for collagen content, concentration, and types. Histologic analysis, reverse transcription-polymerase chain reaction (RT-PCR) of relaxin and relaxin receptor mRNA expression, receptor autoradiography, glomerular isolation/analysis, and serum/urine analysis were also employed. Relaxin treatment of RLX-/- mice was used to confirm the antifibrotic effects of the peptide.
RESULTS: We demonstrate an age-related progression of renal fibrosis in male, but not female, RLX-/- mice with significantly (P < 0.05) increased tissue dry weight, collagen (type I) content and concentration. The increased collagen expression in the kidney was associated with increased glomerular matrix and to a lesser extent, interstitial fibrosis in RLX-/- mice, which also had significantly increased serum creatinine (P < 0.05) and urinary protein (P < 0.05). Treatment of RLX-/- mice with relaxin in established stages of renal fibrosis resulted in the reversal of collagen deposition.
CONCLUSION: This study supports the concept that relaxin may provide a means to regulate excessive collagen deposition during kidney development and in diseased states characterized by renal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149318     DOI: 10.1111/j.1523-1755.2004.00628.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

1.  Glyoxalase I retards renal senescence.

Authors:  Yoichiro Ikeda; Reiko Inagi; Toshio Miyata; Ryoji Nagai; Makoto Arai; Mitsuhiro Miyashita; Masanari Itokawa; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2011-10-12       Impact factor: 4.307

Review 2.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 3.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 4.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

5.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

Review 6.  Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Authors:  Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce
Journal:  Mol Cell Endocrinol       Date:  2019-02-14       Impact factor: 4.102

Review 7.  Heart Disease and Relaxin: New Actions for an Old Hormone.

Authors:  Teja Devarakonda; Fadi N Salloum
Journal:  Trends Endocrinol Metab       Date:  2018-03-08       Impact factor: 12.015

Review 8.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 9.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

10.  Relaxin decreases the severity of established hepatic fibrosis in mice.

Authors:  Robert G Bennett; Dean G Heimann; Sudhir Singh; Ronda L Simpson; Dean J Tuma
Journal:  Liver Int       Date:  2013-07-21       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.